Essential thrombocytosis risk factors: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 10: | Line 10: | ||
**Presence of JAK2 mutation | **Presence of JAK2 mutation | ||
**High white cell count of 15 x 10/L at the time of diagnosis | **High white cell count of 15 x 10/L at the time of diagnosis | ||
**Previous history of thromboticevents | |||
**Previous history of [[bone marrow]] fibrosis | **Previous history of [[bone marrow]] fibrosis | ||
**Female sex | **Female sex | ||
Revision as of 15:18, 6 November 2015
|
Essential thrombocytosis Microchapters |
|
Differentiating Essential thrombocytosis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Essential thrombocytosis risk factors On the Web |
|
American Roentgen Ray Society Images of Essential thrombocytosis risk factors |
|
Risk calculators and risk factors for Essential thrombocytosis risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Risk factors in the development of Essential thrombocytosis are presence of JAK2 gene mutation, high white cell count >15 x 10/L at diagnosis, previous bone marrow fibrosis, age greater than 60 years and female sex.[1]
Risk factors
- Most common risk factor in the development of Essential thrombocytosis is age greater than 60 years.[1] Most patients go undiagnosed until late.
- Other risk factors for ET include:
- Presence of JAK2 mutation
- High white cell count of 15 x 10/L at the time of diagnosis
- Previous history of thromboticevents
- Previous history of bone marrow fibrosis
- Female sex
References
- ↑ 1.0 1.1 Beer PA, Erber WN, Campbell PJ, Green AR (2011). "How I treat essential thrombocythemia". Blood. 117 (5): 1472–82. doi:10.1182/blood-2010-08-270033. PMC 3145107. PMID 21106990.